A Phase II, Multi-center, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Panobinostat (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Novartis
- 14 Jul 2017 Planned End Date changed from 1 Jan 2019 to 3 Jan 2019.
- 14 Jul 2017 Planned primary completion date changed from 30 Jan 2018 to 1 Feb 2018.
- 10 Jun 2017 Biomarkers information updated